ASU researcher awarded $1.25M to develop programmable, targeted drugs
Photo courtesy iStock/Getty Images
In a significant stride for medical research, Hao Yan, a professor in Arizona State University’s School of Molecular Sciences and the Biodesign Center for Molecular Design and Biomimetics, has been awarded a $1.25 million grant from the National Institutes of Health (NIH). The grant, provided by the National Institute of General Medical Sciences (NIGMS), will fund Yan’s innovative research into programmable, targeted therapeutics.
Targeted protein degradation (TPD) is a new approach in drug development that focuses on breaking down disease-causing proteins inside cells. Traditional drugs usually work by blocking the activity of specific proteins. However, about 85% of proteins in cells are considered "undruggable" with these traditional methods because they can't be effectively targeted by small-molecule drugs.
TPD therapies take a different approach by using the cell's natural system for breaking down proteins to completely remove these problematic proteins. This method is especially useful for targeting proteins that are hard to inhibit directly. One type of TPD therapy, called proteolysis-targeting chimeras (PROTACs), uses the cell's ubiquitin-proteasome system — which is like the cell's trash disposal unit — to selectively degrade these tough-to-target proteins. While PROTACs have shown promise and some are already being tested in clinical trials, there are still significant challenges and opportunities for further development in this field.
Yan’s project addresses unmet needs in targeted protein degradation therapeutics and develops a series of programmable and conditional PROTACs enabled by nucleic acid nanotechnology.
“We are excited to receive this award from NIGMS to support our programmable and conditional PROTAC platforms,” Yan said, “and we believe we could utilize the high programmability of DNA nanotechnology to address some of the unmet yet important challenges in this field.”
To improve current methods, developing an effective drug delivery system that can activate the breakdown of target proteins only under certain conditions is crucial. Nucleic acid-based techniques, which have already shown success in medicine with drugs like antisense oligonucleotides (ASOs), offer great potential for advancing targeted protein degradation.
By using the natural programmability of DNA, researchers like Yan aim to create a precise way to deliver these protein-degrading therapies into cells and activate them only when needed.
More University news
ASU Alumni Association to honor 3 outstanding alumni leaders during Homecoming
The Arizona State University Alumni Association will proudly recognize three innovative alumni leaders during the Homecoming Parade and football game against Brigham Young University on Saturday, Nov…
From service to civilian success
Transitioning from military to civilian life is a unique experience that can be challenging for veterans. Some struggle to find their purpose, while others seek a network of people and resources to…
ASU as the 'New American University' sets the model for higher education reform
Arizona State University’s charter is only 46 words long, but it’s a bold promise that’s a model for the reinvention of higher education.The document, formally introduced by ASU President Michael…